The federal securities lawsuit claims that internal dysfunction derailed Rytelo’s rollout. According to the complaint, the company's medical and commercial departments were locked in open conflict, leaving the sales force to approach physicians armed with nothing more than basic FDA prescribing information. This lack of marketing support allegedly left community doctors largely uneducated about the product, causing growth to stall within weeks of the launch.
In section Releases
Geron Corporation Faces Shareholder Investigation Over Rytelo Launch
Shareholders of Geron Corporation are under scrutiny by Kuehn Law, PLLC, as investigators probe whether company leadership breached fiduciary duties. The legal action centers on allegations that executives misrepresented the commercial viability of Rytelo, the firm’s sole product, triggering a rapid plateau in revenue shortly after its market debut.
Kuehn Law is currently seeking investors who held Geron Corporation (NASDAQ: GERN) stock prior to February 28, 2024. Interested parties are directed to contact Sophia Anne Silayan at (833) 672-0814 or via email. The firm operates on a contingency basis, covering all litigation costs for participating shareholders.
Comments (0)
No comments yet. Be the first!